One Plant, One Framework: A Unified, Effect-Based Standard for Cannabis Regulation

Presented by Dr. Del Potter, Ph.D., BioUnbound, Dr. Rachel Knox, MD, MBA, Doctors Knox, ACHEM, ABENA IHR, Thuy Vu, Thuy Vu Consulting LLC, and Jessica Montoya, Drug Policy Watch, this webinar is part of an ongoing AFDO Cannabis, Hemp, and Natural Psychedelics Committee webinar series.

Date: August 7, 2026

Time: 1:30-4 p.m. ET

Abstract:

Cannabis regulation rests on a false choice. Hemp or marijuana, intoxicating or not, natural or synthetic. Those are legal and political categories, not pharmacological ones, and they have built a fragmented system that patients, growers, and regulators all spend their days working around.

Three federal moves are now turning that fragmentation into enclosure: Schedule III rescheduling, the November 12 redefinition of hemp by total THC, and the first patented whole-plant drug moving through the FDA pipeline. Together they push the plant toward a narrow, patent-protected, high-cost lane and fence off everything else, and the first patent-enforcement suits are already reaching operating companies.

The Whole Plant Act, a model law written for any legislature to adopt, answers with a single standard. It regulates cannabinoid products by effect rather than origin, tying classification to measurable product attributes: the degree and onset of impairment, the dose per unit, the route of administration, and the conditions of sale and use.

The session presents the framework and the two instruments built to carry it. The first is an Open Standard tool, a state-by-state diagnostic that scores where a jurisdiction sits against the framework today and maps the statutory steps to adopt it, turning a snapshot of current law into a route to reform. The second is a process authority model, which borrows the food-safety principle that an independent expert body validates a process as safe before a product reaches the public, and applies it to the oversight these products need.